NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient groupNICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, Share XNICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient grouphttps://pharmaphorum.com/news/nice-no-to-roches-risdiplam-for-sma-not-unexpected-says-patient-group/
Novartis pulls rival to Roche’s risdiplam in SMA, says market limitedWhile Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market Share XNovartis pulls rival to Roche’s risdiplam in SMA, says market limitedhttps://pharmaphorum.com/news/novartis-pulls-rival-to-roches-risdiplam-in-sma-says-market-limited/
FDA cues up May verdict for Roche’s SMA challenger risdiplamThe FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision Share XFDA cues up May verdict for Roche’s SMA challenger risdiplamhttps://pharmaphorum.com/news/fda-cues-up-may-verdict-for-roches-sma-challenger-risdiplam/
